August 11, 2026

Germantown’s Precigen Inc. (NASDAQ: PGEN) has turned its first-ever quarterly profit, about one year after regulators gave the company the green light to bring its first product to market. 

In August 2025, the FDA approved Precigen’s immunotherapy treatment Papzimeos as the first treatment of its kind for adults with recurrent respiratory papillomatosis, or RRP. The rare disease causes benign tumors in the respiratory tract and can create life-threatening complications. 

Sales of Papzimeos propelled the biopharmaceutical firm formerly known as Intrexon Corp. to its first quarterly profit since it rebranded as Precigen in 2020 and shifted its focus to drug development.

The company reported net income of $20.1 million for the second quarter as net revenue of Papzimeos more than doubled from the prior quarter, to $53.1 million. In last year's second quarter, before Papzimeos hit the market, Precigen lost $26.6 million.

Subscription required to read.

RICHMOND, VA. August 4, 2026 ‐ BRAINBox Solutions today announced a strategic financing to accelerate the development of point-of-care (PoC) and lab-based devices for its BRAINBox TBI diagnostic/prognostic tests for concussion (also known as mTBI or Acute Traumatic Encephalopathy). The financing included equity funding as well as credit facilities from Pivotal Capital Partners and New Horizon Bank. Specific terms were not disclosed.

“The financing reflects the progress we have made in delivering excellent performance in a proprietary assay format, including through our collaboration with Prolight Diagnostics that has demonstrated its Psyro® PoC platform’s suitability for our TBI test as well as other products in our neurology portfolio,” said Donna Edmonds, BRAINBox’s CEO. “We recently entered a development agreement with Prolight and the funding will enable us to develop advanced hardware and software for commercial device and acquire pilot instruments. Development of a PoC device is an important dimension of our strategy, which is to provide the test in hospital laboratories as well is in other settings such as clinics, ambulances, emergency departments, nursing homes, and athletic facilities.”

GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS), a global biodefense company, today highlighted the increasing importance of biological threat preparedness as allied nations confront an evolving security environment characterized by geopolitical conflict, artificial intelligence (AI) and synthetic biology and growing concern about the potential misuse of biological agents. Defense and public health leaders are addressing the heightened risks of biological incidents, whether naturally occurring outbreaks, accidental releases or deliberate acts, which represent a critical component of national resilience and security planning.

Applications are now being accepted for the BioHealth Capital Region Crab Trap Competition, returning as part of the 12th Annual BioHealth Capital Region Week, taking place September 15, 16, and 17, 2026, at US Pharmacopeia in Rockville, Maryland. Apply today at https://bit.ly/CrabTrap2026.

The Crab Trap Competition highlights promising early-stage biohealth companies developing new technologies, products, and solutions across therapeutics, diagnostics, medical devices, digital health, research tools, and other areas of life sciences innovation. Each year, the competition gives selected entrepreneurs the opportunity to present their companies in front of experienced investors, industry leaders, subject matter experts, and regional ecosystem partners. Prizes include $15,000 in cash and $20,000 in services with more being added before now and the competition.

WASHINGTON, Aug. 3, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") announced that the Company's Board of Directors has appointed Julie Sawyer Montgomery as President and Chief Executive Officer and a member of the Board of Directors, effective October 1, 2026. On that date, Rainer Blair will retire and serve as a senior advisor until March 31, 2027 to ensure a seamless transition.

"In alignment with the Board of Directors' succession planning process, I am pleased to announce the appointment of Julie as our next Chief Executive Officer," said Steven Rales, Chairman of the Board of Directors of Danaher. "We are at a uniquely opportune moment for Danaher, with untapped potential to accelerate growth across the enterprise. Julie has the vision, experience, and proven track record to deliver on that potential. I am confident she will lead our Company into its next phase of growth and value creation with a demonstrated commitment to innovation, commercial excellence, and operational rigor, all grounded in strategy. She is deeply engaged with customers, and a staunch advocate for patients as well as the Company's associates."

The Maryland Department of Commerce has opened the FY2027 Biotechnology Investment Incentive Tax Credit (BIITC) program, which encourages investment in qualified Maryland biotechnology companies. Commerce began accepting Form B applications from Qualified Maryland Biotechnology Companies (QMBCs) on August 4, 2026, and will begin accepting Form A investor applications on August 18. The online investor queue opens September 1, 2026, at 9:00 a.m. EST, with available funding allocated on a first-come, first-served basis.



Eligible investors who invest at least $25,000 in a QMBC may receive an income tax credit equal to 33% of their investment, up to $250,000. Enhanced incentives are available for certain investments, including a 50% credit of up to $500,000 for qualifying companies located in Allegany, Dorchester, Garrett, or Somerset counties, as well as additional enhancements for eligible Opportunity Zone and RISE Zone investments. Businesses and investors interested in participating should review the program requirements carefully, as complete documentation is required and incomplete investor applications will be rejected.

The Frederick National Laboratory for Cancer Research will host its 2026 Technology Showcase on Wednesday, September 9, at the Advanced Technology Research Facility in Frederick, Maryland. The event brings together researchers, industry leaders, investors, and technology transfer professionals for an afternoon focused on innovation, commercialization, and collaboration. The program begins with networking, lunch, and one-on-one partnering, followed by a keynote address from Jeff Allen, Ph.D., President and CEO of Friends of Cancer Research.


Attendees will hear presentations highlighting research capabilities and technologies available through Frederick National Laboratory and the National Cancer Institute, along with funder pitches from organizations including Ecphora Capital, TEDCO, and Blood Cancer United. The agenda also features panels on best practices for partnering with NCI and FNL and strategies for moving technologies efficiently through FDA review, as well as presentations showcasing FNL research tools, software, and NCI technologies.

BioHealth Capital Region Week returns September 15–17, 2026, at US Pharmacopeia in Rockville, Maryland, bringing together leaders from across industry, academia, government, investment, research institutions, economic development, and entrepreneurship.

This year’s theme, “Growing the BioHealth Capital Region of Tomorrow,” reflects a practical question facing the region: How do we turn our scientific assets, federal presence, talent, infrastructure, and industry base into more companies, stronger partnerships, greater investment, and sustained economic growth?

BHCR Week creates three distinct opportunities to take part in that work: the BioHealth Capital Region Forum, the Crab Trap Competition, and the BioHealth Capital Region Investment Conference. Each serves a different audience and purpose, but together they span the full path from ideas and research to company formation, commercialization, financing, and growth.

The Maryland Department of Commerce is sponsoring delegations of medical technology and digital health companies to attend two premier fall 2026 industry events. The MedTech Conference, organized by AdvaMed, runs October 18–21 in Boston and focuses on medical devices, diagnostics, market access, and the evolving regulatory landscape. HLTH USA takes place November 15–18 in Las Vegas and brings together investors, providers, payers, and digital health innovators for networking and partnership building.

Selected companies receive real perks. MedTech delegates get one complimentary All-Access Pass plus promotion through Commerce's marketing channels, while HLTH USA delegates receive two All-Access Passes, branded kiosk space at the Maryland Pavilion, and the same promotional support. Note that travel costs and exhibition space are not covered, and applicants commit to sending their delegates and submitting a brief recap within 30 days of the event.



Applications are due by close of business on August 17, 2026, and require details like a company description, pitch deck, and proof of good standing with the state. Questions can be directed to the Office of Life Sciences at bradley.gillenwater1@maryland.gov before the deadline.

GAITHERSBURG, Md., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on serious liver diseases, today announced that the company has begun enrolling patients in the PERFORMA Phase 3 trial evaluating the efficacy and safety of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH). Pemvidutide is an investigational balanced glucagon/GLP-1 dual receptor agonist also in development for the treatment of alcohol use disorder (AUD) and alcohol-associated liver disease (ALD).

The PERFORMA trial is a global, Phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and clinical outcomes of pemvidutide in MASH patients with moderate to advanced fibrosis. PERFORMA is Altimmune's registrational study for pemvidutide in MASH and will assess the effects of treatment on fibrosis improvement and MASH resolution as well as clinical outcomes. The trial follows positive findings from the IMPACT Phase 2b study and incorporates feedback from the U.S. Food and Drug Administration (FDA) and European regulatory agencies. The 52-week data readout from the trial is anticipated in 2029.

Sponsorship opportunities are available for the 12th Annual BioHealth Capital Region Week, September 15–17, 2026, at US Pharmacopeia in Rockville, Maryland.

Sponsors help keep BHCR Week free to attend while gaining visibility with biohealth leaders, investors, emerging companies, academic institutions, government partners, and regional collaborators across the BioHealth Capital Region Forum, Crab Trap Competition, and Investment Conference.

Sponsorship also provides access to one of the most valuable parts of the week: the VIP Leadership Dinner. This smaller, invite-only gathering brings together senior executives, investors, speakers, public-sector leaders, university partners, and key opinion leaders in a more focused setting than the daytime program. For sponsors, it is an opportunity to build relationships, have higher-value conversations, and connect directly with people who are helping shape the future of the BioHealth Capital Region.

BHCR Week sponsors are recognized across event materials, signage, the registration site, and BHI communications, providing visibility before and during the event. Sponsorship is a strong way to support regional collaboration while positioning your organization in front of the companies, investors, researchers, and partners driving biohealth growth.

To learn more, contact Rich Bendis at rbendis@biohealthinnovation.org and Andy Eckert at aeckert@biohealthinnovation.org.

Sterling, VA — August 4, 2026. Capra Biosciences, Inc., a biomanufacturing company leveraging modular, continuous bioreactor technology to enable flexible, cost-competitive domestic production of pharmaceutical ingredients, today announced continued progress under its project agreement with the Administration for Strategic Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services (HHS).

The additional investment brings Capra's total ASPR funding to approximately $17 million and supports the company's ongoing efforts to onshore the production of critical active pharmaceutical ingredients (APIs) currently sourced almost exclusively overseas.

"Biotechnology offers tremendous power over traditional chemistry for making APIs because it is not limited by supply chains for key starting materials. With our initial ASPR funding, we successfully demonstrated that our modular reactors can produce high-quality APIs. This continued support enables us to take the next step toward cGMP production and regulatory filings that put these molecules on a path to market."

BELTSVILLE, Md., Aug. 10, 2026 (GLOBE NEWSWIRE) — Xcellon Biologics, a U.S.-based Contract Research, Development and Manufacturing Organization (CRDMO) specializing in bioconjugates and complex biologics, today announced that it has signed a definitive agreement to acquire the GMP biologics manufacturing facility from NextCure, Inc. The acquisition marks a transformational milestone in the company’s evolution, establishing Xcellon as an end-to-end CRDMO with integrated capabilities spanning discovery through clinical supply

.

As part of its next phase of growth, Xcellon Biologics appointed co-founder Abhishake Chhibber as Chief Executive Officer to lead the company’s transformation into an end-to-end CRDMO for bioconjugates and complex biologics.

Since launching in 2025, Xcellon has partnered with biotechnology innovators across the United States to advance increasingly sophisticated biologic therapeutics. The acquisition of the 40,000-square-foot NextCure GMP manufacturing facility complements Xcellon’s existing expertise in bioconjugation development and manufacturing, creating an integrated platform designed to accelerate the development of antibody-based therapeutics and other next-generation biologics from early research through clinical manufacturing.

BETHESDA, Md., Aug. 6, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has entered into a non-binding Memorandum of Understanding (MOU) with the Saudi Pharmaceutical Industries and Medical Appliance Company (SPIMACO) for a collaboration to bring the Company's DCVax®-L products and technology to Saudi Arabia. SPIMACO is one of the largest pharmaceutical companies in Saudi Arabia and a leader in 21 markets across the Middle East North Africa (MENA) region.

The MOU establishes a general framework for discussions for the potential collaboration regarding the approval, commercialization, supply and technology transfer of the Company's DCVax®-L product for glioblastoma brain cancer (Product) in Saudi Arabia (Territory). Over time, the collaboration may expand by mutual agreement to include DCVax-L products for other indications in addition to brain cancer, and may expand to include other territories, such as Gulf Cooperation Council (GCC) countries.